The price of imitation version of Adagraxibu

Adagrasib is a targeted anticancer drug that belongs to a class of drugs called KRAS G12C inhibitors. KRAS G12C is a cancer-related mutant associated with a variety of malignant tumors, such as non-small cell lung cancer, colorectal cancer, and pancreatic cancer. This mutant causes tumor cells to overproliferate, grow and spread, making treatment more difficult.

Since adagrasib is not yet available on the domestic market, patients are currently unable to purchase it directly domestically and must obtain it through overseas channels. The price of the original Adagrasibu drug produced in the United States is extremely high, reaching more than 180,000 yuan, making it unaffordable for ordinary families. But what is gratifying is that foreign generic drugs have recently come out. Among them, the generic drug of adagrasibu launched by Lucius Pharmaceuticals in Laos is relatively affordable, priced at about four to five thousand yuan per box, and its pharmaceutical ingredients are basically the same as the original drug.

The unique feature of adagrasib is its ability to targetKRAS G12C mutant, which provides new hope for tumor treatment. By inhibiting the activity of this mutant, it blocks the growth signaling of cancer cells, thereby inhibiting tumor growth and spread.

The discovery of this drug is a major breakthrough because scientists have long sought, without success, ways to directly interfere with the activity of KRAS mutants. The emergence of adagrasib fills this gap and provides a new treatment option for cancer patients with KRAS G12C mutations, especially those who previously lacked effective treatments.

Clinical trials have shown that adagrasib exhibits significant anti-tumor activity in some patients with advanced cancer. Although further studies are still needed to determine its long-term efficacy and safety, adagrasib represents an innovative treatment strategy that brings new hope to the field of cancer treatment.